Why dentistry's AI story is different

In the wider healthcare AI narrative, dentistry occupies a distinctive position. Unlike GP primary care — where AI scribes have achieved rapid adoption driven by the acute administrative burden on NHS practitioners — dental AI has developed primarily around clinical imaging analysis rather than workflow automation. And unlike physiotherapy, where autonomous AI delivery has received regulatory approval, dental AI remains firmly in the assistive category: tools that support clinical decision-making rather than replacing it.

This means dental AI adoption is shaped by a different set of factors. The technology is clinically valuable, but the business case is more complex. The upfront cost is significant. The regulatory pathway is clear but requires CE or UKCA marking. And the workforce is fragmented — NHS dentistry, mixed practices, and fully private practices each have different economic pressures and adoption incentives.

The tools that are live in UK practices

Three products represent the main AI imaging applications with active UK deployment:

Pearl Second Opinion

Pearl is a US-developed AI diagnostic platform that has received CE marking for pathology detection in dental radiographs. (iatroX) It analyses bitewing and periapical X-rays to identify:

Pearl presents findings as overlays on the original radiograph, with confidence scores and highlighted pathology areas. The design intent is to act as a second opinion — catching pathology the clinician might have missed, or confirming findings that are borderline.

AssistDent

Developed at the University of Manchester, AssistDent focuses specifically on earlier detection of approximal caries — decay occurring between adjacent teeth, which is particularly difficult to identify visually and prone to being missed or detected late on radiographs. (iatroX) Its Manchester origins give it a research-grounded validation pathway and particular credibility with NHS-adjacent practices.

Early detection of caries enables more conservative treatment (remineralisation, minimally invasive restoration) rather than the larger interventions required for advanced decay — a better clinical outcome and a cost-saving for NHS dentistry specifically.

DentalMonitoring

DentalMonitoring operates in orthodontics rather than general dentistry. It uses AI image analysis of smartphone photographs taken by patients at home to monitor orthodontic progress — braces wear, aligner fit, treatment trajectory — remotely. (iatroX)

For orthodontic practices, this represents a significant workflow change: routine monitoring appointments that previously required the patient to attend the practice can be conducted remotely, with the AI flagging any cases requiring in-person attention. This increases practice capacity and patient convenience simultaneously.

The £25,000 implementation barrier

The most significant adoption barrier in UK dentistry is cost. A typical AI imaging implementation for a dental practice is estimated at £25,000–£50,000. (Brit Asia Doctors)

This figure encompasses:

Hardware: High-quality digital radiography equipment (if not already digital), intraoral cameras, and practice computers capable of running AI analysis

Software licensing: Annual or per-use licensing fees for AI diagnostic platforms

Training: Staff training on AI tools, workflow integration, and how to communicate AI findings to patients

Practice management integration: Connecting AI outputs to existing patient record systems

For an NHS or mixed practice already operating on thin margins — NHS dentistry in particular has been under severe financial pressure — £25,000–£50,000 is a very significant capital commitment with an uncertain and long payback period.

Private practices are better positioned to absorb these costs, particularly if AI tools can be used to justify premium pricing — demonstrating to patients that more comprehensive diagnostic analysis is included in their treatment.

The clinical evidence: what does AI actually improve?

The British Dental Journal's position — “cautious optimism, combined with rigorous oversight” (Nature / British Dental Journal) — reflects the current state of clinical evidence for dental AI.

The evidence base for AI caries detection is broadly positive. Multiple studies have demonstrated that AI systems perform comparably to experienced dentists on radiographic caries detection tasks — and in some studies, outperform less experienced practitioners. The particularly valuable finding for practice is that AI + clinician combinations tend to outperform either alone: AI catches cases the clinician missed; the clinician provides context and judgment that the AI cannot.

The evidence for clinical outcome improvement — whether AI-assisted diagnosis actually leads to better patient outcomes, not just better detection rates — is more limited and is an active area of ongoing research.

The British Dental Journal's “rigorous oversight” emphasis reflects appropriate caution about AI implementation in clinical settings:

The regulatory pathway: CE marking and UKCA

Post-Brexit, medical devices in Great Britain require UKCA marking (for Great Britain market) or can use CE marking under transitional arrangements. AI diagnostic systems for dental imaging are classified as medical devices and require appropriate conformity assessment.

Pearl has CE marking for its pathology detection capability. For UK practices, verifying the current UKCA status of any AI dental tool is essential before purchase and use — the regulatory landscape has evolved since Brexit and the transitional arrangements for CE marking have been extended multiple times.

The MHRA is the competent authority for medical devices in the UK and maintains guidance on AI-enabled medical devices, including expectations for clinical validation, post-market surveillance, and adverse event reporting.

AI in patient communication and practice management

Beyond diagnostic imaging, AI is beginning to enter dental practices through patient-facing applications:

Appointment booking and recalls: AI-powered scheduling tools can manage patient recall systems, send appointment reminders, and handle routine booking requests without staff intervention. For practices with high patient volumes and administrative teams, this has clear capacity implications.

Patient communication: AI chatbots on practice websites can answer common patient questions, triage urgent enquiries, and collect patient history information before appointments — reducing call volumes and in-appointment administrative time.

Treatment plan explanation: Some AI tools generate patient-friendly explanations of clinical findings and treatment plans from clinical notes, improving informed consent processes and patient understanding.

These applications are lower-cost and lower-regulatory-complexity than diagnostic AI, making them more accessible for the majority of dental practices that cannot yet justify a £25,000 imaging investment.

What NHS dentistry means for AI adoption

The structural context of NHS dentistry in England significantly affects AI adoption economics. NHS dental contracts are paid through Units of Dental Activity (UDAs) — a fixed-price system that creates strong incentives to maximise patient throughput and strong disincentives for capital investment that increases cost without increasing UDA payments.

AI that improves diagnostic quality does not, under the UDA system, directly increase revenue. The patient benefit is real; the practice business case is much harder to construct. This is why AI adoption in NHS dentistry is likely to be driven by commissioner procurement rather than individual practice investment — NHS England or individual ICBs purchasing AI diagnostic tools and making them available to contracted practices.

Private dentistry faces a different calculus. If AI diagnostic tools demonstrably improve clinical outcomes and can be used to differentiate a practice's quality proposition, they can support premium pricing in a market where patients are making discretionary spending choices.

The broader healthcare AI context

Dental AI sits within a broader wave of AI adoption in UK health that is being shaped by MHRA regulatory activity, NHS procurement decisions, and the patient sentiment challenge. CQC research found that 47% of patients have negative feelings toward AI in healthcare versus 35% positive. (RCGP) For dental practices considering AI, this patient sentiment dimension is important: transparency about AI use in diagnosis, and thoughtful communication about its role as a support tool rather than a replacement for clinical judgment, is essential for maintaining patient trust.

Key statistics at a glance

47% of UK patients have negative feelings toward AI in healthcare — patient communication is essential (RCGP / CQC)

MarGen builds content strategies for regulated healthcare and professional services firms. Explore our GEO services.